Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23-33.
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-2760.
Strati P, Ferrajoli A. Treating older patients with chronic lymphocytic leukemia: a personalized approach. Drugs Aging. 2019;36:841-851.
VENCLYXTO (venetoclax). Product Information. European Medicines Agency. Published December 4, 2016. Updated May 7, 2020. Accessed January 22, 2021. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf
IMBRUVICA (ibrutinib). Product Information. European Medicines Agency. Published October 21, 2014. Updated September 14, 2020. Accessed January 22, 2021. https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf
CALQUENCE (acalabrutinib). Product Information. European Medicines Agency. Published November 5, 2020. Updated November 11, 2020. Accessed January 22, 2021. https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_en.pdf
Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787-798.
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43-56.
Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188-1200.
Al-Sawaf O, Zhang C, Robrecht S, et al. Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase 3 CLL14 trial. Blood. 2020;136(suppl 1):22-23. https://doi.org/10.1182/blood-2020-136977
Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169:661-671.
Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188:844-851.
Al-Sawaf, Zhang C, Tandon M, et al. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter, open-label randomized phase 3 CLL14 trial. Presented at: 25th European Hematology Association (EHA) Annual Virtual Congress 2020. Abstract S155.
Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24:4371-4379.
Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Presented at: 24th European Hematology Association Annual Congress. June 13-16, 2019; Amsterdam, the Netherlands. Abstract LB2602.
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020;34:2038-2050.
Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443.
Shanafelt TD, Wang V, Kay NE, et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. Blood. 2019;134(suppl 1):33. https://doi.org/10.1182/blood-2019-126824
Chu CC, Pinney JJ, Blick-Nitko SK, et al. Ibrutinib off-target inhibition inhibits antibody-dependent cellular phagocytosis but not efferocytosis of CLL cells. Blood. 2020;136(suppl 1):45. https://doi.org/10.1182/blood-2020-139483
Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2020;136(suppl 1):16-17. https://doi.org/10.1182/blood-2020-134446

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Barbara F. Eichhorst, MD

Associate Professor
Consultant Hematologist
Department for Internal Medicine
Secretary of the GLLSG
University Hospital of Cologne
Cologne, Germany

Disclosures

Disclosure: Barbara F. Eichhorst, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; ArQule; AstraZeneca; BeiGene; Celgene; Gilead; Janssen; Merck Sharp & Dohme, Corp.; Novartis; Oxford Biomedica; Roche
Served as a speaker or a member of a speakers bureau for: AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Celgene; Gilead; Janssen; Novartis; Roche
Received grants for clinical research from: AbbVie; AstraZeneca; BeiGene; Gilead; Janssen; Roche

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Initial Therapy for the Patient with CLL: What, Who, and How?

Authors: Barbara F. Eichhorst, MD
CPD Released: 2/26/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/26/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology and oncology specialists and pathologists.

The goal of this activity is to provide case-based examples that illustrate key criteria and clinical data to inform decision-making regarding initial treatment selection and management of patients with chronic lymphocytic leukemia (CLL).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data that should inform decision-making for CLL initial therapy
- Patient characteristics that should inform decision-making to optimize initial treatment choice
Have greater competence related to
- Implementing novel oral treatment options for patients with treatment-naive CLL
- Managing adverse events associated with novel oral therapies

Disclosures

Faculty

Barbara F. Eichhorst, MD

Associate Professor
Consultant Hematologist
Department for Internal Medicine
Secretary of the GLLSG
University Hospital of Cologne
Cologne, Germany

Disclosures

Disclosure: Barbara F. Eichhorst, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; ArQule; AstraZeneca; BeiGene; Celgene; Gilead; Janssen; Merck Sharp & Dohme, Corp.; Novartis; Oxford Biomedica; Roche
Served as a speaker or a member of a speakers bureau for: AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Celgene; Gilead; Janssen; Novartis; Roche
Received grants for clinical research from: AbbVie; AstraZeneca; BeiGene; Gilead; Janssen; Roche

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Initial Therapy for the Patient with CLL: What, Who, and How?

Authors: Barbara F. Eichhorst, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 2/26/2021

Valid for credit through: 2/26/2022

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

Page 1 of 14

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Barbara F. Eichhorst, MD

Editors

Sanneke Koekkoek

Tristin Abair, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

Initial Therapy for the Patient with CLL: What, Who, and How?

Target Audience and Goal Statement

Disclosures

Faculty

Barbara F. Eichhorst, MD

Editors

Sanneke Koekkoek

Tristin Abair, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Initial Therapy for the Patient with CLL: What, Who, and How?